Furthermore, the expression and compensation of other sPLA2 isoforms in transgenic animal models is another factor that might result in large phenotypic changes, and thus should also be observed to advance what we know about sPLA2s in metabolic diseases. This evidence concerns the gene PLA2G2D and Other metabolic disease.